Definition of specialty drugs by PBMs and pharmacy executives 2011

This statistic depicts how some pharmacy benefit managements (PBMs) and specialty pharmacy executives define specialty drugs as of 2011. Some 69 percent considered biotechnically engineered drugs as specialty drugs. Generally, specialty drugs are characterized by having high cost per unit; treating complex chronic or life-threatening conditions; requiring special storage, handling or administration; and require significant degree of patient education, monitoring, and management.

Share of indications which define a specialty drug as of 2011*

Share of responses
High-unit cost drugs61%
Drugs requiring special handling or storage69%
Drugs that require special claims processing35%
Drugs that require prior authorization or step therapy28%
Infused drugs63%
Office-administered injectables54%
Self-administered injectables48%
Oral drugs for noncancer treatments37%
Oral oncology agents56%
Biotechnically engineered drugs69%
Other7%
Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

February 2014

Region

United States

Survey time period

2011

Supplementary notes

* As defined by pharmacy benefit managements and specialty pharmacy executives.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pharmaceutical industry in Norway "

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.